T. Rowe Price Associates’s Lipocine LPCN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-10,271
| Closed | -$56K | – | 2911 |
|
|
2023
Q1 | $56K | Sell |
10,271
-591
| -5% | -$3.22K | ﹤0.01% | 2776 |
|
|
2022
Q4 | $71K | Hold |
10,862
| – | – | ﹤0.01% | 2767 |
|
|
2022
Q3 | $84K | Hold |
10,862
| – | – | ﹤0.01% | 2759 |
|
|
2022
Q2 | $148K | Hold |
10,862
| – | – | ﹤0.01% | 2665 |
|
|
2022
Q1 | $253K | Hold |
10,862
| – | – | ﹤0.01% | 2610 |
|
|
2021
Q4 | $183K | Buy |
10,862
+282
| +3% | +$4.75K | ﹤0.01% | 2777 |
|
|
2021
Q3 | $196K | Buy |
10,580
+5,329
| +101% | +$98.7K | ﹤0.01% | 2727 |
|
|
2021
Q2 | $125K | Hold |
5,251
| – | – | ﹤0.01% | 2806 |
|
|
2021
Q1 | $135K | Buy |
+5,251
| New | +$135K | ﹤0.01% | 2751 |
|
|
2020
Q4 | – | Sell |
-1,551
| Closed | -$37K | – | 2699 |
|
|
2020
Q3 | $37K | Buy |
+1,551
| New | +$37K | ﹤0.01% | 2555 |
|